Immatics CEO and leadership

Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries into highly innovative immunotherapies to impact the lives of cancer patients.

Since the foundation, he has served as Managing Director and Chief Scientific Officer, helping to grow the Company from a start-up to a leading biotech player in the field of TCR therapeutics. In 2014, Harpreet became President & CEO of Immatics US, overseeing all operations of Immatics in Houston, Texas to develop next-generation Adoptive Cell Therapies (ACT). In 2019, Harpreet became CEO of Immatics Group. From 2017 to 2020, Immatics signed strategic alliances with Amgen, Genmab, BMS and GSK on 10 programs directed against Immatics’ targets. In July 2020, Immatics listed at NASDAQ. Over the company life-time, Immatics has raised more than $650m from venture capital funding, IPO proceeds and milestone payments to advance its pipeline of TCR-based cell therapies and Bispecifics.

Harpreet is the inventor on numerous granted patents and patent applications and co-author of numerous scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, Lancet Oncology. A scholar of Prof. Hans-Georg Rammensee, Harpreet completed his academic studies by gaining a Ph.D. in immunology awarded “summa cum laude” at the University of Tuebingen, Germany in 2002.

Toni Weinschenk co-founded Immatics Biotechnologies GmbH in 2000. Over the past two decades, Toni Weinschenk has been active in the field of cancer immunology. At Immatics Biotechnologies GmbH, Toni Weinschenk heads the Discovery Department dedicated to target discovery and validation. He is the inventor of Immatics’ proprietary XPRESIDENT® technology platform, which is enabling the discovery and validation of the most comprehensive array of cancer targets derived from both, cell surface and intracellular antigens. Toni Weinschenk has earned the reputation as the world’s leading expert in ultra-sensitive, quantitative and high-throughput mass spectrometry of HLA ligands, a technology that is integral to XPRESIDENT®. Targets identified by XPRESIDENT® have proven to be important assets in several licensing deals with partners from the pharma industry and academia. At Immatics US Inc., he has the role of Chief Technology Officer where he oversees Immatics’ biomarker and other target discovery capabilities. Toni Weinschenk is an inventor on many patents and co-authored publications in the cancer immunology field in prestigious peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Immunological Reviews and Cell Report. Toni Weinschenk studied biochemistry at the University of Tuebingen, Germany and at the Max-Planck-Institute, Munich, Germany.

Arnd Christ joined Immatics in October 2020 and brings nearly two decades of experience serving as CFO of both private and public biotechnology companies.

Before joining Immatics, he was CFO of several companies including InflaRX, Medigene AG, Novimmune SA and Probiodrug AG. Over the course of his career, Arnd Christ completed a broad range of corporate transactions including an IPO, capital raises and licensing deals. Prior to serving as a CFO, he held the position of Financial Director in various corporations related to the former Hoechst Group in Germany and the UK. Arnd Christ holds a master’s degree in business administration from the University of Würzburg, Germany.

As Chief Medical Officer of Immatics, Cedrik Britten, MD, is responsible for the management and global development Immatics’ clinical pipeline.

Cedrik brings over ten years of experience in clinical and preclinical research as well as drug development in the field of immuno-oncology. He most recently served as Vice President and Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline in the United Kingdom, where he was responsible for the early cell therapy pipeline in Oncology R&D which included clinical development to proof-of-concept. In this role, he also established research and development teams and led the development of TCR-T as well as early-stage CAR-T programs. Prior to that, he held various senior positions at BioNTech including Vice President for R&D. During his time at BioNTech, he built and established clinical research teams, was responsible for early drug development and led clinical, as well as non-clinical, oncology development programs for personalized cancer immunotherapy products.

Cedrik Britten graduated from the Johannes Gutenberg-University in Mainz, Germany, with both a medical and doctoral degree.

Rainer Kramer joined Immatics Biotechnologies GmbH in April 2012 from Signature Diagnostics AG where he was member of the Management Board and Chief Business Officer. He is responsible for Immatics’ corporate business development activities, intellectual property and corporate communications.

During his career, he has delivered numerous strategic partnerships and license deals encompassing technology and product deals as well as equity transactions with an aggregate value of more than $3 billion. During the sale of Jerini to Shire in 2008 he was a member of Jerini’s M&A committee and Shire’s appointed principal for the sale of Jerini’s spin out of JPT Peptide Technologies GmbH in 2009. Rainer Kramer has worked in research and business development functions with increasing responsibilities at Amgen Inc., MorphoSys AG, Jerini AG, Shire PLC and Signature Diagnostics AG.

Rainer Kramer holds a Ph.D. from the Max-Planck-Institute for Neurobiology, Martinsried, Germany.

Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries into highly innovative immunotherapies to impact the lives of cancer patients.

Since the foundation, he has served as Managing Director and Chief Scientific Officer, helping to grow the Company from a start-up to a leading biotech player in the field of TCR therapeutics. In 2014, Harpreet became President & CEO of Immatics US, overseeing all operations of Immatics in Houston, Texas to develop next-generation Adoptive Cell Therapies (ACT). In 2019, Harpreet became CEO of Immatics Group. From 2017 to 2020, Immatics signed strategic alliances with Amgen, Genmab, BMS and GSK on 10 programs directed against Immatics’ targets. In July 2020, Immatics listed at NASDAQ. Over the company life-time, Immatics has raised more than $650m from venture capital funding, IPO proceeds and milestone payments to advance its pipeline of TCR-based cell therapies and Bispecifics.

Harpreet is the inventor on numerous granted patents and patent applications and co-author of numerous scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, Lancet Oncology. A scholar of Prof. Hans-Georg Rammensee, Harpreet completed his academic studies by gaining a Ph.D. in immunology awarded “summa cum laude” at the University of Tuebingen, Germany in 2002.